BR9611210A - Composições e processos para tratamento de condições ósseas deficitárias - Google Patents
Composições e processos para tratamento de condições ósseas deficitáriasInfo
- Publication number
- BR9611210A BR9611210A BR9611210-7A BR9611210A BR9611210A BR 9611210 A BR9611210 A BR 9611210A BR 9611210 A BR9611210 A BR 9611210A BR 9611210 A BR9611210 A BR 9611210A
- Authority
- BR
- Brazil
- Prior art keywords
- bone
- compositions
- processes
- ability
- development
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Patente de Invenção: <B>"COMPOSIçõES E PROCESSOS PARA TRATAMENTO DE CONDIçõES óSSEAS DEFICITáRIAS"<D>. Compostos contendo dois sistemas aromáticos covalentemente ligados através de um ligante contendo um ou mais átomos, ou "ligante" definido como incluindo uma ligação covalente por si, de modo a espaçar os sistemas aromáticos a uma distância de 1,5-15<sym> são eficazes nas condições de tratamento associados aos déficits ósseos. Os compostos podem ser administrados aos indivíduos vertebrados sozinhos ou em combinação com agentes adicionais que promovem o desenvolvimento ósseo ou que inibam a ressorção ósseas. Eles podem ser classificados por atividade antes da administração por avaliar sua capacidade de efetuar a transição de um gene repórter acoplado a um promotor associado a uma proteína morfogenética ósse e/ou sua capacidade de estimular o desenvolvimento calvarial nos sistemas animais modelos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US583095P | 1995-10-23 | 1995-10-23 | |
PCT/US1996/017019 WO1997015308A1 (en) | 1995-10-23 | 1996-10-23 | Compositions and methods for treating bone deficit conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9611210A true BR9611210A (pt) | 1999-12-28 |
Family
ID=21717974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9611210-7A BR9611210A (pt) | 1995-10-23 | 1996-10-23 | Composições e processos para tratamento de condições ósseas deficitárias |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0866710A4 (pt) |
JP (1) | JP2000513324A (pt) |
KR (1) | KR19990067010A (pt) |
CN (1) | CN1201393A (pt) |
AU (1) | AU706262B2 (pt) |
BR (1) | BR9611210A (pt) |
CA (1) | CA2235481A1 (pt) |
CZ (1) | CZ115398A3 (pt) |
EA (1) | EA199800393A1 (pt) |
HU (1) | HUP9802319A3 (pt) |
NO (1) | NO981810L (pt) |
PL (1) | PL327617A1 (pt) |
WO (1) | WO1997015308A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL330814A1 (en) | 1996-06-20 | 1999-06-07 | Regents Board Of | Compounds for and methods of delivering pharmaceutical preparations and their application |
WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
US6080779A (en) * | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
US6376476B1 (en) | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
AU8748798A (en) * | 1997-08-22 | 1999-03-16 | Kyowa Hakko Kogyo Co. Ltd. | 4-aminoquinazoline derivatives |
US6649631B1 (en) | 1997-10-23 | 2003-11-18 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating bone deficit conditions |
DE19812204A1 (de) * | 1998-03-19 | 1999-11-04 | Plantamed Arzneimittel Gmbh | Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung |
JP2000004882A (ja) * | 1998-06-18 | 2000-01-11 | Hoechst Marion Roussel Kk | ヒトmp52遺伝子プロモーターおよびこれを用いた有用物質の探索法 |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
ID30132A (id) * | 1998-11-06 | 2001-11-08 | Basf Ag | Turunan-turunan pirazol trisiklik |
US6462036B1 (en) | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
WO2000078351A1 (fr) * | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Promoteurs de l'osteogenese |
WO2001017562A1 (en) * | 1999-09-02 | 2001-03-15 | Yamanouchi Pharmaceutical Co., Ltd. | Osteogenesis promoting agents |
ES2246922T3 (es) * | 1999-12-28 | 2006-03-01 | Eisai Co., Ltd. | Compuestos heterociclicos que tienen grupos de sulfonamida. |
FR2806408B1 (fr) * | 2000-03-17 | 2002-10-11 | Oreal | Composition cosmetique comprenant un derive de furane- naphtoquinone, leur utilisation comme agent colorant et derives |
ATE314363T1 (de) | 2000-06-05 | 2006-01-15 | Austria Wirtschaftsserv Gmbh | Heterocyclische hydrazone als anti-krebs- wirkstoffe |
US6660737B2 (en) | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
EP1500643A4 (en) * | 2002-04-03 | 2007-03-28 | Dainippon Sumitomo Pharma Co | BENZAMIDE DERIVATIVES |
US20050260126A1 (en) * | 2002-08-30 | 2005-11-24 | Yukitsuka Kudo | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
JPWO2004054978A1 (ja) | 2002-12-16 | 2006-04-20 | 株式会社 ビーエフ研究所 | タウ蛋白蓄積性疾患の診断プローブとしてのキノリン誘導体 |
CA2514940A1 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid vr1 receptor |
CA2564085C (en) | 2004-04-30 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
TW200640931A (en) | 2005-02-17 | 2006-12-01 | Wyeth Corp | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
WO2009076792A1 (en) | 2007-12-19 | 2009-06-25 | Givaudan Sa | Cooling compounds |
SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
CA3146333A1 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents |
PL2421533T3 (pl) | 2009-04-22 | 2019-05-31 | Resverlogix Corp | Nowe środki przeciwzapalne |
JP5992049B2 (ja) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | 置換されたキナゾリノンのための経口速放性製剤 |
EP2877454B1 (en) | 2012-07-18 | 2016-11-02 | University College Dublin National University Of Ireland, Dublin | Anti-angiogenic 2-styryl-quinoline compounds |
CN102942515A (zh) * | 2012-10-22 | 2013-02-27 | 暨南大学 | 一种乙烯桥连吲哚化合物及其合成方法和用途 |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
MX2015007921A (es) | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
EP3268007B1 (en) | 2015-03-13 | 2022-11-09 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
CN107019687B (zh) * | 2017-05-08 | 2020-10-27 | 上海市伤骨科研究所 | N-(4-氯苯基)-3-羟基-2-萘甲酰胺类化合物的用途 |
CN111116552B (zh) * | 2020-01-17 | 2022-10-11 | 河北科技大学 | 一种喹唑啉酮类化合物及其制备方法 |
CN114469863B (zh) * | 2021-11-26 | 2023-09-26 | 南方医科大学南方医院 | 甾醇脂质体作为牙髓和牙本质药物传递系统的应用 |
CN116650495B (zh) * | 2021-12-10 | 2024-04-19 | 中南大学湘雅医院 | 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889851A (en) * | 1986-11-21 | 1989-12-26 | Fujisawa Pharmaceutical Co, Ltd. | Benzothiadiazine compounds, and pharmaceutical composition comprising the same |
JP2724396B2 (ja) * | 1987-12-18 | 1998-03-09 | 武田薬品工業株式会社 | 骨粗鬆症予防治療剤 |
EP0536119A4 (en) * | 1989-02-10 | 1993-08-04 | Washington Research Foundation | Immunoregulatory agents |
JPH06192272A (ja) * | 1992-12-24 | 1994-07-12 | Japan Tobacco Inc | 新規なトリアゾロベンゾチアジアジン及びトリアゾロベンゾチアジアゼピン誘導体 |
US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
EP0716086A1 (en) * | 1994-12-09 | 1996-06-12 | Boehringer Mannheim Gmbh | Malonic acid based matrix metalloproteinase inhibitors |
WO1998017267A1 (en) * | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
WO1998025460A1 (en) * | 1996-12-13 | 1998-06-18 | Zymogenetics, Inc. | Compositions and methods for stimulating bone growth |
-
1996
- 1996-10-23 AU AU74710/96A patent/AU706262B2/en not_active Ceased
- 1996-10-23 JP JP09516761A patent/JP2000513324A/ja active Pending
- 1996-10-23 CA CA002235481A patent/CA2235481A1/en not_active Abandoned
- 1996-10-23 CN CN96197827A patent/CN1201393A/zh active Pending
- 1996-10-23 WO PCT/US1996/017019 patent/WO1997015308A1/en not_active Application Discontinuation
- 1996-10-23 HU HU9802319A patent/HUP9802319A3/hu unknown
- 1996-10-23 CZ CZ981153A patent/CZ115398A3/cs unknown
- 1996-10-23 BR BR9611210-7A patent/BR9611210A/pt not_active Application Discontinuation
- 1996-10-23 EA EA199800393A patent/EA199800393A1/ru unknown
- 1996-10-23 PL PL96327617A patent/PL327617A1/xx unknown
- 1996-10-23 KR KR1019980702947A patent/KR19990067010A/ko not_active Application Discontinuation
- 1996-10-23 EP EP96936906A patent/EP0866710A4/en not_active Withdrawn
-
1998
- 1998-04-22 NO NO981810A patent/NO981810L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1201393A (zh) | 1998-12-09 |
EP0866710A1 (en) | 1998-09-30 |
AU706262B2 (en) | 1999-06-10 |
EA199800393A1 (ru) | 1998-12-24 |
CA2235481A1 (en) | 1997-05-01 |
WO1997015308A1 (en) | 1997-05-01 |
AU7471096A (en) | 1997-05-15 |
HUP9802319A2 (hu) | 1999-02-01 |
CZ115398A3 (cs) | 1998-12-16 |
KR19990067010A (ko) | 1999-08-16 |
PL327617A1 (en) | 1998-12-21 |
EP0866710A4 (en) | 2001-07-11 |
NO981810D0 (no) | 1998-04-22 |
HUP9802319A3 (en) | 1999-12-28 |
JP2000513324A (ja) | 2000-10-10 |
NO981810L (no) | 1998-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9611210A (pt) | Composições e processos para tratamento de condições ósseas deficitárias | |
BR9711805A (pt) | Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos | |
BR9917082A (pt) | Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase | |
BR0206689A (pt) | Combinação de probióticos, e, uso desta | |
BR9815159A (pt) | Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
DE69427650D1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
BR0214757A (pt) | Formulações farmacêuticas de derivados de platina | |
HRP20010877B1 (en) | Composition for prevention and treatment of amyloidogenic disease | |
DK0910647T3 (da) | Human DNase i hyperaktive varianter | |
BR0013010A (pt) | Formulação de cloreto de sódio de moxifloxacina | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
BR9811093A (pt) | Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo) | |
BR0313239A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças | |
ES2109260T3 (es) | Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas. | |
ES2133329T3 (es) | Variantes de il-3 humana. | |
TR200101649T2 (tr) | Piperazin türevleri. | |
BR9810703A (pt) | Composição farmacêutica, e, processos para a preparação da mesma, e para tratar um distúrbio de agregação de plaqueta | |
TR200100637T2 (tr) | Yeni doğal ürün türevleri | |
BR0006088A (pt) | Derivados de proteìna c | |
BR9908716A (pt) | Tratamento de disfunção sexual em certos grupos de pacientes | |
BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
BR9915071A (pt) | Utilização de uma proteìna ompa de enterobactéria ou de um de seus fragmentos | |
BR9612355A (pt) | Agentes de ligação com os receptores de ácido hialurÈnico e o uso destes. | |
BR9809457A (pt) | Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law |